In April 2005, the FDA issued a special public health advisory concerning the use of atypical antipsychotic drugs in elderly patients for all-label uses. These drugs are commonly used to control behavioral symptoms of agitation in elderly patients with dementia. The FDA data found that elderly patients given atypical antipsychotics for this reason were up to 1.7 times more likely to die during treatment. What did the FDA issue in April 2005 regarding the use of atypical antipsychotic drugs in elderly patients?
1) A warning about the increased risk of death in elderly patients given atypical antipsychotics
2) A recommendation to use atypical antipsychotics in elderly patients with dementia
3) A statement about the benefits of atypical antipsychotics in elderly patients
4) A guideline for the dosage of atypical antipsychotics in elderly patients